Compare NVGS & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVGS | ENOV |
|---|---|---|
| Founded | 1997 | 1995 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Fluid Controls |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2013 | 2008 |
| Metric | NVGS | ENOV |
|---|---|---|
| Price | $23.07 | $19.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $21.50 | ★ $47.38 |
| AVG Volume (30 Days) | 332.7K | ★ 1.2M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $6.36 |
| Revenue Next Year | N/A | $5.31 |
| P/E Ratio | $13.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.08 | $18.52 |
| 52 Week High | $24.36 | $34.28 |
| Indicator | NVGS | ENOV |
|---|---|---|
| Relative Strength Index (RSI) | 60.78 | 30.35 |
| Support Level | $21.41 | N/A |
| Resistance Level | $23.16 | $27.20 |
| Average True Range (ATR) | 0.55 | 1.27 |
| MACD | 0.07 | -0.62 |
| Stochastic Oscillator | 72.46 | 3.33 |
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture). The company plays a vital role in the globalised liquefied gas supply chain, providing gas transportation solutions for energy companies, industrial users, and commodity traders.
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.